CRISPR Therapeutics (CRSP) Misses Q2 EPS by 6c
CRISPR Therapeutics (NASDAQ: CRSP) reported Q2 EPS of ($1.49), $0.06 worse than the analyst estimate of ($1.43).
For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.